Komori
Denka (4061) · InitiativeFirst stated

Discontinuation of norovirus vaccine development

First written in FY2024-Q3. . Latest entry: FY2024-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Norovirus vaccine development discontinuation and impairmentA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3First statedAnnual report

    「In “Life Innovation,” we recorded an impairment loss of ¥6,786 million because the discontinuation of norovirus vaccine development made it impossible to generate the revenue originally anticipated.」

    Disclosed the discontinuation of norovirus vaccine development for the first time and recorded an impairment loss of ¥6,786 million because the revenue originally anticipated could no longer be expected.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Denka's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.